Saturday, May 9, 2026Aggregating 2,418 sources · Updated 38 seconds agoNYC 54° · LON 47° · TOK 61°
Health

Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown

TWSJ·1d ago·3 min read
Photograph via The Wall Street Journal
RSS SUMMARY · AGGREGATED FROM TWSJ

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.

Continue Reading

The full story continues on The Wall Street Journal.

Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.